Results 151 to 160 of about 2,625,517 (304)
Emotion Regulation Difficulties in Autism‐PTSD Co‐Occurrence
Autism Research, EarlyView.ABSTRACT Autistic individuals face an increased risk of experiencing traumatic events and of being significantly affected by them, whether these events are life‐threatening or social in nature. Emotion regulation (ER) difficulties are central to both conditions, yet their role in this neuropsychiatric co‐occurrence remains under‐researched.
Eldar Fayena +6 more
wiley +1 more source
Autism Research, EarlyView.ABSTRACT Antidepressant prescribing and autism diagnoses have increased in recent years. We aimed to describe and compare trends in antidepressant prescribing, indications, doses and durations in autistic and non‐autistic males and females in the United Kingdom (UK) from 1997 to 2023.
Aws Sadik +7 more
wiley +1 more source
Scientific ReportsPsychological distress represents a growing concern in contemporary society, with its prevalence often exacerbated by various demographic and health-related factors.
Mehdi Mirzaei-Alavijeh +5 more
doaj +1 more source
Autism Research, EarlyView.ABSTRACT Non‐suicidal self‐injury (NSSI) is prevalent among autistic adolescents and adults, yet research on its clinical characteristics, functions, and association with suicidal thoughts and behaviors (STBs) in this population remains limited. This study compared these domains between autistic adolescents and adults with and without recent NSSI.
Safaa Eldeeb +7 more
wiley +1 more source
, 2017 [[abstract]]Background: Diabetes and hypertension are respectively the second and third leading cause of death in Belize. The daily demands of the comorbid disease cause patients to develop psychological distress.
Quetzal, Tracy Maria, 柯翠希
core
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
British Journal of Clinical Pharmacology, EarlyView.Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
Exploring new avenues: Psychedelic‐assisted therapy for young people
British Journal of Clinical Pharmacology, EarlyView.Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou +3 more
wiley +1 more source
Evidence on the relationship between green and blue spaces and mental health in regional areas of Australia is limited. This study assessed associations between green space, blue space, green-blue space (GBS), and psychological distress in regional ...
Biddle, Stuart J.H. +3 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu +7 more
wiley +1 more source